ArticleCancer chemotherapy and pharmacology2023

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

Drew W Rasco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.